Ping-Chih Ho, of the Ludwig Institute for Cancer Research Lausanne, and his team discover a possible way of outsmarting melanomas that currently elude immune checkpoint blockade therapy.
Pr Ho and his team have uncovered a cellular mechanism by which melanomas that fail to respond to checkpoint blockade may be made susceptible to such immunotherapies. The same study also identifies an existing diabetes drug that could be used to accomplish that feat. The paper (first author: Wan-Chen Cheng) was reported in Nature Immunology (24th January 2019).